{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T22:22:55Z","timestamp":1770070975214,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2003,4,1]],"date-time":"2003-04-01T00:00:00Z","timestamp":1049155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2003,4,1]],"date-time":"2003-04-01T00:00:00Z","timestamp":1049155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2003,4,1]]},"DOI":"10.1038\/sj.jhh.1001541","type":"journal-article","created":{"date-parts":[[2003,4,24]],"date-time":"2003-04-24T17:03:24Z","timestamp":1051203804000},"page":"265-270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products"],"prefix":"10.1038","volume":"17","author":[{"given":"K","family":"\u0160ebekov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Gazd\u00edkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Syrov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Bla\u017e\u00ed\u010dek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Schinzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Heidland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Spustov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Dz\u00farik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2003,4,11]]},"reference":[{"issue":"Suppl 1","key":"BF1001541_CR1","first-page":"S12","volume":"58","author":"W Siems","year":"2002","unstructured":"Siems W et al. Oxidative stress in chronic renal failure as a cardiovascular risk factor. Clin Nephrol 2002; 58 (Suppl 1): S12\u2013S19.","journal-title":"Clin Nephrol"},{"key":"BF1001541_CR2","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1046\/j.1523-1755.1999.00422.x","volume":"55","author":"P Stenvinkel","year":"1999","unstructured":"Stenvinkel P et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899\u20131911.","journal-title":"Kidney Int"},{"key":"BF1001541_CR3","first-page":"1","volume":"9","author":"E Ritz","year":"1994","unstructured":"Ritz E, Deppisch R, Nawroth P . Toxicity or uraemia: does it come of AGE? Nephrol Dial Transplant 1994; 9: 1\u20132","journal-title":"Nephrol Dial Transplant"},{"key":"BF1001541_CR4","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/ki.1997.429","volume":"52","author":"TP Degenhardt","year":"1997","unstructured":"Degenhardt TP et al. The serum concentration of the advanced glycation end product N\u025b-(carboxymethyl)lysine is increased in uremia. Kidne Int 1997; 52: 1064\u20131067.","journal-title":"Kidne Int"},{"key":"BF1001541_CR5","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1681\/ASN.V781198","volume":"7","author":"T Miyata","year":"1996","unstructured":"Miyata T et al. Accumulation of albumin-linked and free form pentosidine in circulation of uremic patients with end stage renal failure: renal implications in pathophysiology of pentosidine. J Am Soc Nephrol 1996; 7: 1198\u20131206.","journal-title":"J Am Soc Nephrol"},{"key":"BF1001541_CR6","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s004670100038","volume":"16","author":"K \u0160ebekov\u00e1","year":"2001","unstructured":"\u0160ebekov\u00e1 K et al. Plasma levels of advanced glycation end products in children with renal disease. Ped Nephrol 2001; 16: 1105\u20131112.","journal-title":"Ped Nephrol"},{"key":"BF1001541_CR7","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1046\/j.1523-1755.1999.00302.x","volume":"55","author":"T Miyata","year":"1955","unstructured":"Miyata T et al. Alterations in non-enzymatic glycation in uremia: origin and significance of \u2018carbonyl stress\u2019 in long term uremic complications. Kidney Int 1955; 55: 389\u2013399.","journal-title":"Kidney Int"},{"key":"BF1001541_CR8","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/ki.1997.160","volume":"51","author":"T Miyata","year":"1997","unstructured":"Miyata T et al. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 1997; 51: 1170\u20131181.","journal-title":"Kidney Int"},{"key":"BF1001541_CR9","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1113\/expphysiol.1997.sp004028","volume":"82","author":"R Bucala","year":"1997","unstructured":"Bucala R . Lipid and lipoprotein modification by AGEs: role in atherosclerosis. Exp Physiol 1997; 82: 327\u2013337.","journal-title":"Exp Physiol"},{"key":"BF1001541_CR10","first-page":"1013","volume":"44","author":"PJ Thornalley","year":"1988","unstructured":"Thornalley PJ . Cell activation by glycated proteins, AGE receptors, receptor recognition factors and functional classification of AGE. Cell Mol Biol 1988; 44: 1013\u20131023.","journal-title":"Cell Mol Biol"},{"key":"BF1001541_CR11","first-page":"230","volume":"12","author":"AF Perna","year":"1999","unstructured":"Perna AF, Castaldo P, Ingrosso D, De Santo NG . Homocysteine, a new cardiovascular risk factor, is also a powerful uremic toxin. J Nephrol 1999; 12: 230\u2013240.","journal-title":"J Nephrol"},{"key":"BF1001541_CR12","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1056\/NEJM199804093381507","volume":"338","author":"GN Welch","year":"1998","unstructured":"Welch GN, Loscalzo JL . Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 1024\u20131050.","journal-title":"N Engl J Med"},{"key":"BF1001541_CR13","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/ki.1996.186","volume":"49","author":"V Witko-Sarsat","year":"1996","unstructured":"Witko-Sarsat V et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304\u20131313.","journal-title":"Kidney Int"},{"key":"BF1001541_CR14","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/00005344-199203000-00005","volume":"19","author":"M Chopra","year":"1992","unstructured":"Chopra M et al. Antioxidants effects of angiotensin-converting enzyme (ACE) inhibitors: free radical and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl-and non-sulfhydryl-containing ACE inhibitors. J Cardiovasc Pharmacol 1992; 19: 330\u2013340.","journal-title":"J Cardiovasc Pharmacol"},{"key":"BF1001541_CR15","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1097\/01.ASN.0000032418.67267.F2","volume":"13","author":"T Miyata","year":"2002","unstructured":"Miyata T et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 2002; 13: 2478\u20132487.","journal-title":"J Am Soc Nephrol"},{"key":"BF1001541_CR16","doi-asserted-by":"publisher","first-page":"R572","DOI":"10.1152\/ajpregu.2000.278.3.R572","volume":"278","author":"EM De Cavanagh","year":"2000","unstructured":"De Cavanagh EM, Inserra F, Ferder L, Fraga CG . Enalapril and captopril enhance glutathione-dependent antioxidant defenses in mouse tissues. Am J Physiol Regul Integr Comp Physiol 2000; 278: R572\u2013R577.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"BF1001541_CR17","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1080\/15216540050033177","volume":"49","author":"KZ Kedziora-Kornatowska","year":"2000","unstructured":"Kedziora-Kornatowska KZ, Luciak M, Paszkowski J . Lipid peroxidation and activities of antioxidant enzymes in the diabetic kidney: effect of treatment with angiotensin convertase inhibitors. IUBMB Life 2000; 49: 303\u2013307.","journal-title":"IUBMB Life"},{"key":"BF1001541_CR18","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1097\/00005344-200106000-00010","volume":"37","author":"H Tsutsui","year":"2001","unstructured":"Tsutsui H et al. Effects of ACEI inhibition on left ventricular failure and oxidative stress in Dahl salt-sensitive rats. J Cardiovasc Pharmacol 2001; 37: 725\u2013733.","journal-title":"J Cardiovasc Pharmacol"},{"key":"BF1001541_CR19","first-page":"BR69","volume":"8","author":"V Tesar","year":"2002","unstructured":"Tesar V et al. Influence of losartan and enalapril on urinary excretion of 8-isoprostane in experimental nephrotic syndrome. Med Sci Monit 2002; 8: BR69\u2013BR74.","journal-title":"Med Sci Monit"},{"key":"BF1001541_CR20","first-page":"669","volume":"35","author":"G M\u00fcnch","year":"1997","unstructured":"M\u00fcnch G et al. Determination of advanced glycation end products in serum by fluorescene spectroscopy and competitive ELISA. Eur J Clin Chem 1997; 35: 669\u2013677.","journal-title":"Eur J Clin Chem"},{"key":"BF1001541_CR21","first-page":"276","volume":"54","author":"A Gerdemann","year":"2001","unstructured":"Gerdemann A et al. Low molecular but not high molecular AGEs are removed by high flux hemodialysis. Clin Nephrol 2001; 54: 276\u2013283.","journal-title":"Clin Nephrol"},{"key":"BF1001541_CR22","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/(SICI)1096-9136(199710)14:10<832::AID-DIA492>3.0.CO;2-9","volume":"14","author":"AC Mellinghoff","year":"1997","unstructured":"Mellinghoff AC et al. Formation of plasma advanced glycosylation end-products (AGEs) has no influence on plasma viscosity. Diabet Med 1997; 14: 832\u2013836.","journal-title":"Diabet Med"},{"key":"BF1001541_CR23","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/0304-4165(85)90142-4","volume":"843","author":"M Tschuchida","year":"1985","unstructured":"Tschuchida M et al. Fluorescent substances in mouse and human sera as a parameter of in vivo lipoperoxidation. Biochim Biophys Acta 1985; 843: 214\u2013220.","journal-title":"Biochim Biophys Acta"},{"key":"BF1001541_CR24","first-page":"549","volume":"29","author":"B Vester","year":"1991","unstructured":"Vester B, Rasmussen K . High performance liquid chromatography method for rapid and accurate determination of homocysteine in plasma and serum. Eur J Clin Chem Clin Biochem 1991; 29: 549\u2013554.","journal-title":"Eur J Clin Chem Clin Biochem"},{"key":"BF1001541_CR25","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1159\/000063558","volume":"20","author":"B Descamps-Latscha","year":"2002","unstructured":"Descamps-Latscha B, Jungers P, Witko-Sarsat V . Immune system dysregulation in uremia: role of oxidative stress. Blood Purif 2002; 20: 481\u2013484.","journal-title":"Blood Purif"},{"key":"BF1001541_CR26","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev.med.46.1.223","volume":"46","author":"M Brownlee","year":"1995","unstructured":"Brownlee M . Advanced protein glycosylation in diabetics and aging. Annu Rev Med 1995; 46: 223\u2013234.","journal-title":"Annu Rev Med"},{"key":"BF1001541_CR27","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.2337\/diab.45.3.S73","volume":"S3","author":"S Horiuchi","year":"1996","unstructured":"Horiuchi S et al. Advanced glycosylation end products and their recognition by macrophage derived cells. Diabetes 1996; S3: S73\u2013S76.","journal-title":"Diabetes"},{"key":"BF1001541_CR28","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/BF00403957","volume":"39","author":"A Gugliucci","year":"1996","unstructured":"Gugliucci A, Bendayan M . Renal fate of circulating advanced glycation end products (AGEs): evidence for absorbtion and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia 1996; 39: 149\u2013160.","journal-title":"Diabetologia"},{"key":"BF1001541_CR29","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S0168-8278(01)00232-X","volume":"36","author":"K ebekov\u00e1","year":"2002","unstructured":"S\u0160 ebekov\u00e1 K, Kupc\u0160ov\u00e1 V, Schinzel R, Heidland A . Markedly elevated levels of plasma advanced glyca-tion end products in patients with liver cirrhosis\u2014amelioration by liver transplantation. J Hepatol 2002; 36: 66\u201371.","journal-title":"J Hepatol"},{"key":"BF1001541_CR30","first-page":"379","volume":"45","author":"M Friedlander","year":"1996","unstructured":"Friedlander M et al. The advanced glycation end product pentosidine and monocyte activation in uremia. Clin Nephrol 1996; 45: 379\u2013382.","journal-title":"Clin Nephrol"},{"key":"BF1001541_CR31","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000045934","volume":"87","author":"R Schinzel","year":"2001","unstructured":"Schinzel R, Muench G, Heidland A, \u0160ebekov\u00e1 K . Advanced glycation end products in end-stage renal disease and their removal. Nephron 2001; 87: 295\u2013303.","journal-title":"Nephron"},{"key":"BF1001541_CR32","doi-asserted-by":"publisher","first-page":"3274","DOI":"10.2337\/diabetes.51.11.3274","volume":"51","author":"JM Forbes","year":"2002","unstructured":"Forbes JM et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 2002; 51: 3274\u20133282.","journal-title":"Diabetes"},{"key":"BF1001541_CR33","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1159\/000057478","volume":"25","author":"K S\u0160ebekov\u00e1","year":"1999","unstructured":"S\u0160ebekov\u00e1 K et al. Advanced glycation end products levels in subtotally nephrectomized rats: beneficial effects of angiotensis II receptor 1 antagonist losartan. Mineral Electrolyte Metab 1999; 25: 380\u2013383.","journal-title":"Mineral Electrolyte Metab"},{"key":"BF1001541_CR34","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S0272-6386(99)70071-5","volume":"34","author":"EM De Cavanagh","year":"1999","unstructured":"De Cavanagh EM et al. Higher levels of antioxidant defences in enalapril-treated versus non-enalapril-treated hemodialysis patients. Am J Kidney Dis 1999; 34: 445\u2013455","journal-title":"Am J Kidney Dis"},{"key":"BF1001541_CR35","first-page":"529","volume":"48","author":"G Floris","year":"1983","unstructured":"Floris G, Dezso B, Medgyesi GA, Fust G . Effect of angiotensin II on macrophage functions. Immunology 1983; 48: 529\u2013535.","journal-title":"Immunology"},{"key":"BF1001541_CR36","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/0014-5793(94)00531-1","volume":"347","author":"AW Hahn","year":"1994","unstructured":"Hahn AW, Jonas U, Buhler FR, Resink TJ . Activation of human peripheral monocytes by angiotensin II. FEBS Lett 1994; 347: 178\u2013180.","journal-title":"FEBS Lett"},{"key":"BF1001541_CR37","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1016\/S0735-1097(99)00495-7","volume":"34","author":"L Gullestadt","year":"1999","unstructured":"Gullestadt L et al. Effect of high- versus low-dose angiotensin-converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol 1999; 34: 2061\u20132067.","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1001541.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1001541","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1001541.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T18:14:11Z","timestamp":1647540851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1001541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,4,1]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,4,1]]}},"alternative-id":["BF1001541"],"URL":"https:\/\/doi.org\/10.1038\/sj.jhh.1001541","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"value":"0950-9240","type":"print"},{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,4,1]]},"assertion":[{"value":"29 May 2002","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2002","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2002","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2003","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}